Compare FIP & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIP | LRMR |
|---|---|---|
| Founded | 2021 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 568.4M | 455.8M |
| IPO Year | 2021 | 2014 |
| Metric | FIP | LRMR |
|---|---|---|
| Price | $4.64 | $4.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $11.00 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 1.6M | 1.2M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | ★ 16.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $502,520,000.00 | N/A |
| Revenue This Year | $58.19 | N/A |
| Revenue Next Year | $30.58 | $1,816.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 51.59 | N/A |
| 52 Week Low | $3.06 | $2.72 |
| 52 Week High | $6.69 | $6.42 |
| Indicator | FIP | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 60.20 | 60.40 |
| Support Level | $4.56 | $4.21 |
| Resistance Level | $4.66 | $5.35 |
| Average True Range (ATR) | 0.34 | 0.24 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 97.23 | 79.19 |
FTAI Infrastructure Inc is engaged in five segments; Railroad segment, which includes eight freight railroads and one switching company that provide rail service to certain manufacturing and production facilities; the Jefferson Terminal segment, which consists of a multi-modal crude oil and refined products terminal and other related assets; The Repauno segment, which consists of a deep-water port located along the Delaware River with an underground storage cavern, a multipurpose dock, a rail-to-ship transloading system, and multiple industrial development opportunities; Power and Gas segment, which comprised Long Ridge, a multi-modal terminal located along the Ohio River; and Sustainability and Energy Transition segment, which comprised of Aleon/Gladieux, Clean Planet, and CarbonFree.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.